Would you like the opportunity to meet with representatives from Otsuka?
Are you are researcher or company looking for potential partnership opportunities, licensing, or other collaborations with Otsuka?
Join Life Science Washington Institute, Life Science Washington, and Otsuka for a VIP Forum March 15 & 16, 2023. Download the Otsuka Factsheet here.
There are two ways to participate in this event:
- RSVP to the Plenary Session and Networking Reception (No cost to attend!)
- Apply to meet with Otsuka representatives (deadline extended to February 25)
For more information or questions, contact aylin@lswinstitute.org !
Otsuka Areas of Interest:
Clinical Stage Development (from 1 year prior to IND to Phase 3 Study) for:
- Psychiatry:
Mood/psychotic disorder, impulse/conduct disorder, stress/anxiety disorder, neuropsychiatric symptoms, autism, Tourette syndrome, unmet needs including treatment-resistant patients and add-on therapy
- Neurology*:
Neurodegenerative disease, seizure disorder, repeat disease, Rett-syndrome, Angelman/Prader-Willi syndrome. Both disease modifier and symptom treatment for major neurology diseases like AD, PD, MS, and orphan neurology diseases.
- Nephrology:
Glomerular and tubular chronic kidney diseases, immune-mediated kidney diseases, complement-mediated kidney diseases, acute kidney injury, kidney transplant
- Immunology:
Systemic lupus erythematosus, rare autoimmune diseases including SLE but not including immuno-oncology.
- Digital**:
Digital medicines, digital therapeutics, digital biomarkers and diagnostics, connected care platforms, analytics, remote monitoring, data collection
*Symptomatic and disease-modifying treatments
** Area of Interest TA: psychiatry, neurology, and nephrology
